This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Should You Invest in the VanEck Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
ResMed (RMD) Q4 Earnings Beat Estimates, Gross Margin Up
by Zacks Equity Research
ResMed (RMD) posts better-than-expected Q4 results with continued strength in sleep and respiratory care devices sales performance.
J&J (JNJ) to Stop Selling Talc-based Baby Powder From 2023
by Zacks Equity Research
J&J (JNJ) will stop selling its talcum-based baby powder globally from next year. Though reports claim that the use of the talc causes cancer, JNJ maintains its stance that this product is safe.
STERIS (STE) Gains From Cantel Buyout, Supply Chain Issue Stays
by Zacks Equity Research
Revenue growth at STERIS' (STE) Applied Sterilization Technologies is driven by increased demand from medical device and biopharma customers.
Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Haemonetics (HAE) posts better-than-expected results in Q1 with robust contributions from the Hospital business.
Seagen's (SGEN) Cancer Drugs Aid Growth, Stiff Rivalry a Woe
by Zacks Equity Research
Seagen (SGEN) focuses on improving sales of its marketed drugs approved for different types of cancer indications. Stiff competition in the market remains a woe.
Omnicell (OMCL) Q2 Earnings Miss Estimates, Gross Margin Down
by Zacks Equity Research
Robust sales contribution from product and services segments drove Omnicell's (OMCL) Q2 top line.
Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth
by Zacks Equity Research
Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.
SmileDirectClub (SDC) Q2 Earnings Lag Estimates, Guidance Cut
by Zacks Equity Research
SmileDirectClub (SDC) witnesses a drop in both net and financing revenues on a year-over-year basis.
Q2 Earnings Scorecard and Analyst Reports for Roche, Adobe & McDonald's
by Sheraz Mian
Today's Research Daily features update on the Q2 earnings season and new research reports on Roche (RHHBY), Adobe (ADBE), and McDonald's (MCD).
Insulet (PODD) Q2 Earnings Miss Estimates, '22 Sales View Up
by Zacks Equity Research
Insulet (PODD) posts better-than-expected revenues in Q2 with robust contributions from Total Omnipod.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Analyst Blog Highlights Exxon Mobil, Merck & Co, Chevron, American Electric Power and The Southern
by Santanu Roy
Exxon Mobil, Merck & Co, Chevron, American Electric Power and The Southern are part of Zacks Analyst Blog.
NuVasive (NUVA) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
NuVasive's (NUVA) Q2 revenues outpaced the consensus mark with strong sales across U.S. Spinal Hardware and Surgical Support businesses.
5 High-Flying U.S. Corporate Giants to Buy Despite Volatility
by Nalak Das
We have narrowed our search to five U.S. corporate giants. These are; XOM, CVX, AEP, MRK and SO.
3 Great Stocks to Buy in August for Safety and Long-Term Growth
by Benjamin Rains
The episode focuses on three stocks--Humana, Merck, and Dollar Tree--that have proven they can climb during 2022's falling market and operate businesses that are likely to withstand any economic downturn or possible recession.
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Myriad Genetics (MYGN) Q2 Earnings Top, Gross Margin Down
by Zacks Equity Research
Myriad Genetics (MYGN) posts better-than-expected results in Q2 with contributions from most product lines.
Corcept (CORT) Down on Q2 Earnings Miss, Revenues Rise Y/Y
by Zacks Equity Research
Corcept's (CORT) earnings miss estimates in second-quarter 2022 while revenues beat the same. Shares down.
Syneos Health (SYNH) Q2 Earnings Top Estimates, Cuts '22 View
by Zacks Equity Research
Syneos Health (SYNH) posts better-than-expected earnings in the second quarter and robust results across the Clinical Solutions and Commercial Solutions businesses.
Bruker (BRKR) Q2 Earnings Match Estimates, '22 Sales View Down
by Zacks Equity Research
Robust performance across the BSI and BEST segments drove Bruker's (BRKR) second-quarter top line.
Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat
by Zacks Equity Research
Mirati Therapeutics' (MRTX) Q2 earnings and sales beat the mark. The company plans to start early-stage clinical studies for a SOS1 inhibitor by year-end.
Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut
by Zacks Equity Research
Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.
CVS Health (CVS) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
CVS Health (CVS) posts better-than-expected results in Q2, with robust performances across all operating segments driving the top line.
Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.